In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Reviva Pharmaceuticals Holdings (RVPH - Research Report), with a price target of $3.00. The company's shares opened today at $0.70.According to TipRanks, McCarthy is an analyst with an average return of -36.2% and a 17.69% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Reviva Pharmaceuticals Holdings with a $3.00 average price target.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-reviva-pharmaceuticals-holdings-rvph?utm_source=advfn.com&utm_medium=referral
Reviva Pharmaceuticals (NASDAQ:RVPH)
Gráfico Histórico do Ativo
De Ago 2023 até Set 2023 Click aqui para mais gráficos Reviva Pharmaceuticals.
Reviva Pharmaceuticals (NASDAQ:RVPH)
Gráfico Histórico do Ativo
De Set 2022 até Set 2023 Click aqui para mais gráficos Reviva Pharmaceuticals.